Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab for anti-NMDAR and anti-LGI1 autoimmune encephalitis
PACTR202308468197623Phase 3Recruiting
- Sponsor
- Roche
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of satralizumab in anti-NMDA receptor encephalitis and Anti-leucine-rich glioma inactivated 1 encephalitis, sponsored by Roche. Primary endpoints: Proportion of participants with mRS improvement at Week 24 without rescue therapy and Percentage of participants with adverse events. Started Sep 2022; status: recruiting.
02
Drugs
satralizumab
03
Conditions
anti-NMDA receptor encephalitisAnti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on PACTR202308468197623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308468197623.